We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors -- a CESAR study (Central European Society for Anticancer Drug Research -- EWIV).
- Authors
Hofheinz, R.-D.; Dittrich, C.; Jakupec, M. A.; Drescher, A.; Jaehde, U.; Gneist, M.; Keyserlingk, N. Graf v.; Keppler, B. K.; Hochhaus, A.
- Abstract
The article presents an abstract of the medical research "Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors -- a CESAR study (Central European Society for Anticancer Drug Research -- EWIV)," by R.-D. Hofheinz, C. Dittrich, M.A. Jakupec, A. Drescher, U. Jaehde, M. Gneist, N. Graf v. Keyserlingk, B.K. Keppler and A. Hochhaus. In order to determine the maximum tolerated dose of FFC I I, the dose-limiting toxicity and a suitable dose for phase II trials an open-label dose-escalation phase I clinical trial was initiated during the research.
- Subjects
MEDICAL research; DRUGS; TUMORS; CLINICAL trials; DITTRICH, C.; JAKUPEC, M. A.
- Publication
International Journal of Clinical Pharmacology & Therapeutics, 2005, Vol 43, Issue 12, p590
- ISSN
0946-1965
- Publication type
Abstract
- DOI
10.5414/CPP43590